COVID Cuts: A brief summary of this week’s COVID-19 clinical research

Home/COVID Cuts: A brief summary of this week’s COVID-19 clinical research

COVID Cuts: A brief summary of this week’s COVID-19 clinical research

COVID Cuts: A brief summary of this week’s COVID-19 clinical research

Vaccine Update: 

The mRNA-1273 vaccine (from Moderna and NIAID) induced anti-SARS-COV-2 immune responses (anti-Spike-2P glycoprotein antibody) in all participants and no trial-limiting safety concerns were identified.

Epidemiology:

During hospital-wide SARS-CoV-2 antibody (Ab) screening in healthcare workers (HCW) and staff in Belgium, 6.4% had IgG antibodies for SARS-CoV-2

During hospital-wide SARS-CoV-2 Ab screening in HCW and staff at Mass Gen Hospital (performed in 3 phases), 12.9% had positive results for SARS-CoV-2, and universal masking policy was associated with a significantly lower rate of SARS-CoV-2

Overall SARS-CoV-2 PCR- positivity rates of HCW in a pediatric setting in Paris was 2.3% (compared to 2.8% in an associated adult setting)

Treatment:

Within a retrospective review of critically ill adults with SARS-CoV-2 pneumonia, no difference was found between hydroxychloroquine or lopinavir/ritonavir compared to standard of care

Case Reports: 

Child with Guillain-Barre syndrome after COVID-19

Child receiving remdesivir during induction chemotherapy for newly diagnosed pediatric acute lymphoblastic leukemia with concomitant SARS-CoV-2 infection

Child with oral ulceration as an early feature of multisystem inflammatory syndrome in children (MIS-C)

Two children with COVID-19 positive PCR swab upon MIS-C presentation

Immunology:

Humoral and circulating follicular helper T cell responses in a cross-sectional adult cohort who had recovered from COVID-19 infection

Description of a rapid antibody discovery platform that isolated hundreds of human monoclonal antibodies again SARS-CoV-2 spike protein

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

 

|2020-07-17T11:56:24-04:00July 17th, 2020|COVID-19 Literature|0 Comments

About the Author: Megan McHenry

Megan McHenry
Megan S. McHenry, MD, MS, FAAP is a pediatrician and an Assistant Professor of Pediatrics in the Ryan White Center for Pediatric Infectious Disease and Global Health at Indiana University School of Medicine. Dr. McHenry's research focuses on early childhood development in children living in resource-limited settings. This work is frequently aligned with community-engaged research and dissemination and implementation science frameworks. She primarily conducts research in collaboration with the Academic Model for Providing Access to Healthcare (AMPATH) Research Network in Kenya. Dr. McHenry currently has a career development award through the National Institutes of Health to develop a neurodevelopmental screening program for children born to HIV-infected mothers in Kenya. Dr. McHenry is also the Director of Pediatric Global Health Education and a co-Director of the Morris Green Physician-Scientist Development Program at Indiana University School of Medicine. In additional to global health lectures, she also educates residents and students on early childhood development, basic biostatistical techniques, research methodologies, and research ethics. She mentors multiple pediatric fellows, residents, and medical students interested in early childhood development within global contexts.

Get Involved with Indiana CTSI